Inhaler article

Abstract

The invention relates to an inhaler article. The inhaler article comprises a tubular body. The tubular body comprises an inner airflow channel extending between a mouth end of the tubular body and a distal end of the tubular body. The inhaler article comprises a cavity for receiving an aerosol forming substrate. The cavity is arranged in the tubular body between the mouth end and the distal end. The inhaler article comprises a resealable retention element arranged at a position distal to the cavity. The resealable retention element is configured to be switchable between an open position and a closed position. In the open position, the distal end of the tubular body is fluidly connected to the cavity. In the closed position, the distal end of the tubular body is fluidly isolated from the cavity. The invention further relates to an inhaler system comprising the inhaler article and a holder.

Description

[0001] INHALER ARTICLE

[0002] The present invention relates to an inhaler article. The present invention further relates to an inhaler system comprising the inhaler article and a holder.

[0003] Inhaler articles are known, for example dry powder inhaler articles. Certain inhaler articles retain capsules containing dry powder. These capsules may be activated by piercing the capsule wall. Active substances of the dry powder may then be taken up by an airflow through the inhaler article and may be transported to a user’s mouth for inhalation. Powder residues in the inhaler article may inadvertently leak out of a distal end of the article after use.

[0004] It would be desirable to provide an inhaler article that reduces or avoids leakage. It would be desirable to provide an inhaler system which may be handled comfortably by a user.

[0005] According to an embodiment of the present invention there is provided an inhaler article. The inhaler article may comprise a tubular body. The tubular body may comprise an inner airflow channel extending between a mouth end of the tubular body and a distal end of the tubular body. The inhaler article may comprise a cavity for receiving an aerosol forming substrate. The cavity may be arranged in the tubular body between the mouth end and the distal end. The inhaler article may comprise a resealable retention element arranged at a position distal to the cavity. The resealable retention element may be configured to be switchable between an open position and a closed position. In the open position, the distal end of the tubular body may be fluidly connected to the cavity. In the closed position, the distal end of the tubular body may be fluidly isolated from the cavity.

[0006] According to an embodiment of the present invention there is provided an inhaler article. The inhaler article comprises a tubular body. The tubular body comprises an inner airflow channel extending between a mouth end of the tubular body and a distal end of the tubular body. The inhaler article comprises a cavity for receiving an aerosol forming substrate. The cavity is arranged in the tubular body between the mouth end and the distal end. The inhaler article comprises a resealable retention element arranged at a position distal to the cavity. The resealable retention element is configured to be switchable between an open position and a closed position. In the open position, the distal end of the tubular body is fluidly connected to the cavity. In the closed position, the distal end of the tubular body is fluidly isolated from the cavity.

[0007] The resealable retention element may be configured to switch between the open position and the closed position in dependence of the presence or absence of a pressure difference in the inner airflow channel generated between the mouth end and the distal end of the tubular body. The resealable retention element's ability to switch between open and closed positions based on the pressure difference within the inner airflow channel may bring several advantages. It may ensure efficient airflow control. It may prevent leakage when the inhaler is not in use. It may promote maintaining cleanliness. Overall, it may improve one or more of user experience, dosing accuracy, and device reliability.

[0008] The resealable retention element may be configured to move towards the open position when a negative pressure is applied at the mouth end. The resealable retention element may be configured to move back towards the closed position in absence of the negative pressure. This may ensure optimal drug delivery. As the negative pressure subsides, the element may revert to the closed position, minimizing any potential loss.

[0009] As used herein, the term “negative pressure” refers to a condition in which the pressure of a fluid or gas is lower than the atmospheric pressure of its surroundings. In other words, it is a state where the pressure within a confined space is less than the pressure outside that space. Negative pressure may cause fluids or gases to be drawn into the lower- pressure area from higher-pressure regions, creating a pulling or suction effect.

[0010] The resealable retention element may comprise a flexible portion. The flexible portion may be movable between a relaxed configuration when the resealable retention element is in the closed position and a tense configuration when the resealable retention element is in the open position.

[0011] As used herein, the term “flexible portion” refers to a specific segment or part of an object or material that is capable of bending, moving, or changing shape without breaking or losing its structural integrity. This flexibility may allow the portion to adapt to different positions or conditions while returning to its original form when the external force causing the bending is removed.

[0012] In its closed configuration, the flexible portion may be in a state of relaxation. Conversely, when the resealable retention element transitions to the open configuration, the flexible portion may switch into a tense configuration. This may provide a controlled and deliberate manoeuvring between the distinct positions. This mechanism may contribute to the efficacy of the element, enabling it to seamlessly establish a secure seal while being in the closed state, and facilitating unimpeded airflow upon the open state.

[0013] The resealable retention element may be configured as a diskette. The diskette may have the shape of a cylinder. A cylinder axis of the diskette may be arranged to coincide with a longitudinal central axis of the inhaler article. The diskette may have the shape of a right circular cylinder. The right circular cylinder may be a flat cylinder. As used herein, the term “flat cylinder” refers to a cylinder having a diameter of the cylinder exceeding a height of the cylinder along the cylinder axis. A diameter of the diskette-shaped resealable retention element may be between 5 millimeters and 13 millimeters, preferably between 6 millimeters and 11 millimeters, more preferably between 7 millimeters and 9 millimeters. A height of the diskette-shaped resealable retention element may be between 0.1 millimeter and 4 millimeters, preferably between 0.1 millimeter and 3 millimeters, more preferably between 0.1 millimeter and 2 millimeters.

[0014] The resealable retention element may comprise one or more weakening lines. The one or more weakening lines may provide one or more flexible flaps to the resealable retention element. The flexible portion may be provided by the one or more flexible flaps of the resealable retention element.

[0015] The one or more flexible flaps may collectively constitute the flexible portion of the resealable retention element. The incorporation of these flaps by the weakening lines, may endow the resealable retention element with the necessary adaptability for its operational modes.

[0016] The one or more weakening lines may be perforation lines. The one or more weakening lines may be cut lines.

[0017] The resealable retention element may comprise two orthogonally arranged weakening lines to provide four equally sized flexible flaps. The resealable retention element may comprise two orthogonally arranged cut lines to provide four equally sized flexible flaps.

[0018] The resealable retention element may be a diskette and may comprise two orthogonally arranged weakening lines to provide four equally sized flexible flaps. The resealable retention element may be a diskette and may comprise two orthogonally arranged cut lines to provide four equally sized flexible flaps.

[0019] The weaking lines may serve to create four equally sized flexible flaps. This arrangement may ensure a balanced distribution of flexibility across the diskette's structure. This arrangement may optimize the responsiveness and adaptability during transitions between operational states.

[0020] The resealable retention element may comprise a one-way valve. The one-way valve may comprise a valve flap being movable between the closed position and the open position. This mechanism may enable unidirectional airflow control. This mechanism may permit inhalation while preventing exhalation or backflow. The mobility of the valve flap may facilitate its shift from closed to open positions. This may ensure seamless and controlled inhalation.

[0021] The inhaler article may comprise a distal end. The inhaler article may comprise a proximal end opposing the distal end. The proximal end may be a mouth end. The proximal end may comprise a mouthpiece.

[0022] The inhaler article may comprise a front plug. The front plug may be arranged at or near the distal end of the inhaler article. The “front plug” may also be referred to as “terminal plug”. The terms “front plug” and “terminal plug” are used synonymously herein. The front plug may be arranged at the distal end of the tubular body. The front plug may be arranged at the distal end of the inhaler article. The front plug may be a flanged front plug.

[0023] The inhaler article may comprise a flanged front plug arranged at the distal end of the tubular body. The distal end of the tubular body may be at least partially closed by the flanged front plug. The terms “flanged front plug” and “flanged terminal plug” are used synonymously herein.

[0024] The resealable retention element may be affixed to the flanged front plug.

[0025] The resealable retention element may be affixed to an inside face of the flanged front plug.

[0026] The flanged front plug may serve the purpose of partially or fully closing off the distal end of the tubular body. This arrangement may contribute to the controlled management of airflow. It may enhance the inhalation process. It may promote effective delivery of active substances to a user.

[0027] The resealable retention element may be affixed to an outside face of the flanged front plug. The arrangement may optimize space utilization while maintaining the element's functionality. By being situated on the outer face of the plug, the retention element may remain easily accessible for operation while still effectively contributing to the inhaler article's overall design and airflow control.

[0028] The resealable retention element may be affixed to the distal end of the tubular body by a connection wrapper. The connection wrapper may facilitate a secure and reliable connection between the element and the tubular body. This may ensure the retention element's proper positioning and functionality.

[0029] The connection wrapper may be a paper overwrap. This type of wrapper may provide a practical and accessible means of securing the resealable retention element to the distal end of the tubular body. The utilization of a paper overwrap may ensure a functional and user-friendly connection while maintaining a cohesive aesthetic within the inhaler article's design.

[0030] The inhaler article may comprise a retention plug. The retention plug may be positioned between the cavity and the proximal end. The retention plug may be positioned spatially between the cavity and the proximal end. The retention plug may be positioned spatially between the cavity and the proximal end along a longitudinal axis of the inhaler article.

[0031] This placement may serve to segregate the cavity from the proximal end, creating a barrier within the inhaler article. This configuration may contribute to the controlled movement of substances within the device and may enhance the overall functionality of the inhaler article. The retention plug may comprise bioplastic. The use of bioplastics may align with environmentally conscious practices and offers a sustainable option for the construction of the retention plug. The use of bioplastics may contribute to reduced environmental impact and may promote the adoption of eco-friendly alternatives in the design of the inhaler article. As used herein, the term “bioplastic” refers to a type of plastic material derived from renewable biological sources, such as plants, algae, or other organic materials. Unlike traditional plastics that are derived from fossil fuels, bioplastics are created using natural feedstocks that can be replenished, reducing the dependence on non-renewable resources and mitigating the environmental impact associated with traditional plastic production.

[0032] The resealable retention element may comprise at least one of tobacco, cotton, paper, rayon, cork, latex, a starch-based plastic material, and silicone.

[0033] The resealable retention element could potentially incorporate any one of the following materials: tobacco, cotton, paper, rayon, cork, latex, a starch-based plastic material, or silicone. These materials may offer a range of options to suit different functional and design requirements for the retention element. Each material choice may bring its unique characteristics, contributing to the overall performance and versatility of the element within the inhaler article.

[0034] The tubular body may comprise cardboard. This material choice may offer a combination of structural integrity and recyclability, making it a suitable option for forming the main body of the inhaler article. The use of cardboard may align with sustainable practices. The use of cardboard may provide a lightweight yet durable framework for the device.

[0035] The cavity may comprise the aerosol-forming substrate.

[0036] The cavity may be a capsule cavity configured to receive a capsule comprising the aerosol-forming substrate. The cavity may comprise a capsule. The cavity may comprise a capsule comprising the aerosol-forming substrate. The aerosol-forming substrate may be provided in form of particles as described herein. The aerosol-forming substrate may be a powder. The aerosol-forming substrate may be a dry powder.

[0037] The cavity being a capsule cavity may ensure that the inhaler article is tailored for holding and facilitating the delivery of the specific aerosol-forming substrate capsules. It may optimize the compatibility between the inhaler article and the intended aerosol-forming substrate delivery mechanism.

[0038] The capsule may be a pierceable capsule. The pierceable capsule may comprise pharmaceutically active particles. The pierceable capsule may comprise pharmaceutically active particles in form of a dry powder. The pharmaceutically active particles may comprise nicotine. As used herein, the term “aerosol-forming substrate” also encompasses dry powders known for use in dry powder inhalers. The pierceable capsule may house pharmaceutically active particles in the form of a dry powder. Optionally, these particles may include nicotine. This configuration may be particularly suited for delivering pharmaceutically active particles, through inhalation, allowing for efficient and targeted administration.

[0039] The resealable retention element may be a sponge- or foam-like element. The sponge- or foam-like element may comprise a sponge- or foam-like material. The sponge- or foam-like material may be any type of sponge known to the skilled person. For example, a polymeric sponge, a cellulose-based sponge, a synthetic sponge, or any combination thereof. A cellulose-based sponge may advantageously be fully sustainable.

[0040] The density of the sponge- or foam-like element together with the elasticity of the constituting material may define the efficacy of the element in opening and closing following insertion into and removal from the holder. The thickness of the sponge- or foam-like element may be varied for optimizing the sealing efficiency and efficacity in dependence of a specific embodiment. For example, a force needed for insertion may be reduced when reducing the thickness and vice versa.

[0041] The sponge- or foam-like element may comprise one or more weakening lines. The weakening lines of the sponge- or foam-like element may be provided as cutting lines. Various cutting shapes are possible. By varying the cutting shapes, the behavior of the element in opening and closing following insertion into and removal from the holder may be varied. For example, a force needed for insertion may be reduced when increasing the number of cutting lines. By varying the cutting shapes, the sponge- or foam-like element may thus be optimized in dependance of the requirements of a specific embodiment.

[0042] The sponge- or foam-like element may comprise no cutting lines. The sponge- or foam-like element may comprise one single linear cutting line. The sponge- or foam-like element may comprise two straight cutting lines. The sponge- or foam-like element may comprise two perpendicular straight cutting lines. The two cutting lines may cross each other. The sponge- or foam-like element may comprise multiple straight lines. The sponge- or foam-like element may comprise multiple straight lines crossing each other at same or different angles resulting in an asterisk-like shape.

[0043] The one or more cutting lines may be provided such that they do not completely protrude through the sponge- or foam-like element. The one or more cutting lines may be provided such that they do not completely protrude through the sponge- or foam-like element in a direction parallel to the longitudinal axis of the inhaler article when the the sponge- or foam-like element is installed in the inhaler article.

[0044] The one or more cutting lines may be provided by pre-cutting into a section of a sheet-like precursor of the sponge- or foam-like element. The pre-cutting may be performed before bringing the precursor of the sponge- or foam-like element into its final shape to obtain the final sponge- or foam-like element.

[0045] For example, the sponge- or foam-like element may have a cylindrical shape. The cylindrical shape may be configured to closely fit into or onto the tubular body. The cylindrical shape may be configured to have an outer diameter which exceeds an inner diameter of the tubular body. Thereby, the sponge- or foam-like element may be compressed when being inserted into the tubular body. This compression may improve adherence of the sponge- or foam-like element in the tubular body.

[0046] The sponge- or foam-like element may be initially provided as a sheet or stripe of material which is then rolled inside a cylindrical wall of the tubular body. The sheet or stripe of material may comprise one or more pre-cuts provided along a length of the sheet or stripe. Each pre-cut may be provided as a cutting line, the cutting line extending in a direction along a width sheet or stripe in perpendicular to the length of the sheet or stripe. The cutting lines may be configured not to completely penetrate through the width of the sheet or stripe such that the sheet or stripe is not cut into plural pieces.

[0047] For example, the sheet or stripe of material may comprise plural pre-cuts arranged along the length of the stripe or sheet such that, once the sheet or stripe is rolled along is length and then inserted into the tubular body, an asterisk-like shape of the cutting lines is formed.

[0048] The sponge- or foam-like element may be manufactured by providing a precursor of the sponge- or foam-like element in form of a sheet or stripe, the sheet or stripe being made of a sponge- or foam-like material. Optionally, one or more pre-cuts may be cut into the sheet or stripe at different positions along the length of the sheet or stripe. The optional pre-cuts are provided such that they do not extent fully through the width of the sheet or stripe, such that the sheet or stripe remains intact. The sheet or stripe, optionally comprising the pre-cuts, is then rolled along its length into a cylindrical form. Thereby, the final resealable retention element in form of a cylindrical sponge- or foam-like element is provided, optionally comprising one or more cutting lines, for example a plurality of cutting lines in an asterisk-like shape.

[0049] The sponge- or foam-like element may be provided with one or more cutting lines, or without any cutting lines. When no cutting lines are present, the elasticity of the material alone may allow for an easy and convenient insertion of the inhaler article into the holder, and a subsequent return to the original shape on removal of the article from the holder. The sponge- or foam-like element may be of any color, for example white.

[0050] The sponge- or foam-like element may be provided as a single-piece element. The sponge- or foam-like element may be provided as a monolithic piece. The sponge- or foamlike element may be provided as multiple layers of thin sponges or foams. The sponge- or foam-like element may be provided in dry form. The sponge- or foamlike element may be provided in humid form, for example having a water content of at least 1 percent by weight, optionally at least two percent by weight, optionally at least 5 percent by weight, optionally at least 10 percent by weight. Providing a humid sponge- or foam-like element may improve its capability of retaining powder released from a capsule after use, in particular dry powder.

[0051] The resealable retention element may be provided as a film. The film may be formed from a film-forming material. The film-forming material may be a water-based binder. The water-based binder may comprise an acrylic copolymer. The water-based binder may be cross-linkable by UV (ultraviolet) light. The water-based binder may be a water-based binder as those available from Swiss company “Archroma” under the tradename “Appretan®”. “Appretan®” is a film, comprising natural materials, which may be renewable.

[0052] The resealable retention element provided as a film may be used in an inhaler article comprising a flanged front plug of the tubular body. The resealable retention element provided as a film may be used in an inhaler article comprising a curled distal end. The resealable retention element provided as a film may be used in an inhaler article comprising an open tubular body.

[0053] The resealable retention element provided as a film may be substantially transparent. As used herein, the term “substantially transparent” refers to an object having a transparency for visible light in the range of about 400 nanometers to about 700 nanometers of at least 80 percent, preferably at least 85 percent, more preferably at least 90 percent, more preferably at least 95 percent.

[0054] The resealable retention element provided as a film may have a thickness in a range from 1 micrometer to 5000 micrometers, preferably 10 micrometers to 2000 micrometers. The thickness may be measured in a direction parallel to the longitudinal axis of the inhaler article when the resealable retention element is installed in the inhaler article.

[0055] The film-forming material may be provided as a liquid solution. The liquid solution may be applied on flanged or curled tubes or on an open tubular body. For example, the liquid solution may be applied manually by using a paint-brush or tip-dipping the stick into the solution. For example, the liquid solution may be applied by spray application.

[0056] Once applied, the liquid solution typically needs from 5 minutes to 30 minutes to dry and settle, depending on the specific solution and on environmental conditions. The drying step may be accelerated. For example, the drying time may be shortened by employing a drying step. The drying step may comprise guiding the inhaler articles into a drying chamber. For example, a water-based binder which is cross-linkable by UV light may be used, and the drying step may be accelerated by using an UV lamp to accelerate settling and drying. This may allow to reduce the time of settling to few seconds. By reducing the drying time, manufacturing speed may be enhanced. Manufacturing costs may thereby be reduced.

[0057] After drying, the resealable retention element provided as a film may be substantially transparent. After drying, the thickness of the resealable retention element provided as a film may be in a range from 1 micrometer to 5000 micrometers, preferably 10 micrometers to 2000 micrometers.

[0058] The dried layer forming the film may be maintained as a closed layer in the final inhaler article. The closed layer may be perforated only during insertion of the inhaler article into the holder by means of a piercing means of the holder. The dried layer may be cut or perforated in the final inhaler article before use, for example cut in the middle. This may facilitate insertion of the inhaler article into the holder.

[0059] According to an embodiment of the present invention there is provided an inhaler system, comprising the inhaler article as described herein and a holder. The holder may comprise a holder cavity configured to receive at least a distal portion of the inhaler article.

[0060] The resealable retention element of the inhaler article may be configured to form an interference fit with a corresponding face of the holder. The resealable retention element may be designed to establish an interference fit with a corresponding surface on the holder. This design may ensure a secure connection between the resealable retention element and the holder. The interference fit may add stability, contributing to the overall functionality and reliability of the inhaler system.

[0061] The holder may comprise a piercing means arranged for piercing into the cavity of the inhaler article when the inhaler article is being received in the holder cavity. The piercing means may be arranged for piercing a capsule comprised in the cavity of the inhaler article. By the piercing action, the capsule may be opened and an aerosol-forming substrate, for example a dry powder may be released and may be taken up by the airflow through the article.

[0062] The piercing means may allow for seamless integration and activation of the inhaler article within the holder. The piercing means may enhance user convenience by automating the process of preparing the inhaler article for use upon insertion into the holder cavity.

[0063] As used herein, the terms ‘tubular’, ‘tubular unit’, ‘tubular component’, ‘tubular element’, ‘tubular body’, and ‘tubular shape’ refer to three-dimensional objects and three- dimensional geometric shapes comprising a bottom basal plane, a top basal plane, and a sidewall circumscribing a hollow interior, the sidewall being arranged between the bottom basal plane and the top basal plane. The sidewall extends along a longitudinal axis of the tubular body between the bottom basal plane and the top basal plane. The longitudinal axis may be perpendicular to one or both of the bottom basal plane and the top basal plane. A bottom base of the tubular body lies within the bottom basal plane. A top base of the tubular body lies within the top basal plane. A cross-sectional shape of one or both of the bottom and top bases may be circular. A cross-sectional shape of one or both of the bottom and top bases may be non-circular, for example elliptic, stadium-shaped, or rectangular. One or both of the bottom base and the top base may be at least partly open to provide an internal hollow passage of the tubular body.

[0064] The tubular body may have the shape of a right circular hollow cylinder. The tubular body may have the shape of a non-circular hollow cylinder, for example an elliptic hollow cylinder, or a stadium-shaped hollow cylinder. The tubular body may have the shape of a hollow cuboid.

[0065] The longitudinal axis of the tubular body may be arranged in parallel to the longitudinal axis of the inhaler article. A longitudinal central axis of the tubular body may coincide with a longitudinal central axis of the inhaler article.

[0066] As used herein, the term “resealable” refers to the capability to be sealed or closed again after having been opened. In other words, the resealable retention element may be securely closed one or more times after having opened. This may maintain the integrity of its contents and preventing leakage or exposure to the external environment.

[0067] As used herein, the term “fluidly isolated” refers to a state in which substances, usually fluids like liquids or gases, are effectively separated or kept apart from each other, preventing or reducing their interaction or exchange. When two components are fluidly isolated, there is a barrier or mechanism in place that prevents or reduces the flow or transfer of substances between them, maintaining distinct boundaries. As used herein, the term “fluidly isolated” may further refer to a state in which a barrier or mechanism between two components prevents or reduces migration of powder particles between the two components. Particle sizes of the powders may comprise particle diameters in one or both of a nanometer range and a micrometer range.

[0068] According to an embodiment of the present invention there is provided an inhaler article. The inhaler article comprises a tubular body. The tubular body comprises an inner airflow channel extending between a mouth end of the tubular body and a distal end of the tubular body. The inhaler article comprises a cavity for receiving an aerosol forming substrate. The cavity is arranged in the tubular body between the mouth end and the distal end. The inhaler article comprises a resealable retention element arranged at a position distal to the cavity. The resealable retention element is configured to be switchable between an open position and a closed position.

[0069] In the closed position, a portion of the airflow channel between the distal end of the tubular body and the cavity may be closed. In the closed position, a portion of the airflow channel between the distal end of the tubular body and the cavity may be closed so as to reduce or prevent migration of particles between the distal end of the tubular body and the cavity. In the closed position, a portion of the airflow channel between the distal end of the tubular body and the cavity may be closed so as to reduce or prevent leakage of particles from the cavity out of the distal end of the tubular body. In the closed position, a cross- sectional area of a portion of the airflow channel between the distal end of the tubular body and the cavity may be smaller than in the open position.

[0070] In the open position, the portion of the airflow channel between the distal end of the tubular body and the cavity is open. In the open position, the distal end of the tubular body may be fluidly connected to the cavity.

[0071] In the closed position, migration of particles from the cavity into the distal end of the tubular body may be prevented or reduced in comparison to the open position. In the closed position, the distal end of the tubular body may be fluidly isolated from the cavity.

[0072] According to an embodiment of the present invention there is provided an inhaler article. The inhaler article comprises a tubular body. The tubular body comprises an inner airflow channel extending between a mouth end of the tubular body and a distal end of the tubular body. The inhaler article comprises a cavity for receiving an aerosol forming substrate. The cavity is arranged in the tubular body between the mouth end and the distal end. The inhaler article comprises a resealable retention element arranged at a position distal to the cavity. The resealable retention element is configured to be switchable between an open position and a closed position. The inhaler article is configured, such that, in the closed position, a cross-sectional area of a portion of the airflow channel between the distal end of the tubular body and the cavity is smaller than in the open position. The inhaler article may be configured, such that a cross-section of the airflow channel between the distal end of the tubular body and the cavity is open in the open position and is closed or blocked in the closed position.

[0073] The inhaler body may resemble a smoking article or cigarette in size and shape. The inhaler body may have an elongated body extending along the longitudinal axis of the inhaler article. The inhaler body may have a substantially uniform outer diameter along the length of the elongated body. The inhaler body may have a circular cross-section that may be uniform along the length of the elongated body. The inhaler body may have an outer diameter in a range from about 6 mm to about 10 mm, or from about 7 mm to about 10 mm, or about 7 mm to about 9 mm, or about 7 mm to about 8 mm or about 7.2 mm. The inhaler body may have a length (along the longitudinal axis) in a range from about 40 mm to about 80 mm, or from about 40 mm to about 70 mm, or about 40 mm to about 50 mm, or about 45 mm.

[0074] The inhaler body may comprise the tubular body. The inhaler body may be the tubular body. The inhaler article may have an open distal end or upstream-most end defined by a tubular element defining a central passage. The open central passage may define a cylindrical open aperture extending from the capsule cavity to the open distal end or upstream-most end of the inhaler article. The open tubular element defining an open central passage may have a length in a range from about 3 mm to about 12 mm, or from about 3 mm to about 7 mm or about 4 mm to about 6 mm, or about 5 mm.

[0075] The open tubular element defining an open central passage may be formed of a cellulose material. The open tubular element defining an open central passage may be formed of a cellulose acetate material. Preferably the open tubular element is formed of a biodegradable material. The open tubular element defining an open central passage may have a thickness in a range from about 0.5 mm to about 1.5 mm, or about 0.5 mm to about 1 mm. The open tubular element may be the tubular body and the open distal end may be at least partly closed by the resealable retention element in the closed position.

[0076] The inhaler article may comprise a filter element. The filter element may be located downstream of the capsule cavity. The filter element located downstream of the capsule cavity may extend from the capsule cavity to the mouthpiece end of the inhaler article. The filter element may have a length in a range from about 10 mm to about 30 mm, preferably from about 15 mm to about 25 mm and more preferably from about 20 mm to about 22 mm.

[0077] The capsule cavity may define a cylindrical space configured to contain a capsule (the capsule may have an obround shape or a circular cross-section, for example). The capsule cavity may have a substantially uniform or uniform diameter along the length of the capsule cavity. The capsule cavity may have a fixed cavity length. The capsule cavity has a cavity inner diameter, orthogonal to the longitudinal axis, and the capsule has a capsule outer diameter. The capsule cavity may be sized to contain an obround capsule. The capsule cavity may have a substantially cylindrical or cylindrical cross-section along the length of the capsule cavity. The capsule cavity may have a uniform inner diameter. The capsule may have an outer diameter that is about 80% to about 95% of the inner diameter of the capsule cavity. The configuration of the capsule cavity relative to the capsule may promote limited movement of the capsule during activation or piercing of the capsule. The capsule cavity may be defined by an open tubular element. The open tubular element may be joined between and in abutting alignment with the open tubular element forming the distal end of the inhaler article and the filter element. These elements may be joined with a wrapper. The open tubular element defining the capsule cavity may be formed of a biodegradable material, such as cardboard or paperboard.

[0078] The configuration of the capsule cavity relative to the capsule may promote the capsule to rotate with stability within the capsule cavity. The longitudinal axis of the capsule may rotate with stability co-axially with the longitudinal axis of the inhaler body during inhalation. The configuration of the capsule cavity relative to the capsule may promote the capsule to rotate with some shaking within the capsule cavity.

[0079] Stable rotation refers to the longitudinal axis of the inhaler body being substantially parallel or co-axial with the axis of rotation of the capsule. Stable rotation may refer to the absence of procession of the rotating capsule. Preferably the longitudinal axis of the inhaler body may be substantially coextensive with the axis of rotation of the capsule. Stable rotation of the capsule may provide a uniform entrainment of a portion of nicotine particles from the capsule over two or more, or five or more, or ten or more “puffs” or inhalations by a user.

[0080] The capsule may be sealed within the inhaler article prior to consumption. The inhaler article may be contained within a sealed or airtight container or bag. The inhaler article may include one or more peelable or removable seal layers to cover the one or more air inlet channels or the air outlet or mouthpiece of the inhaler article.

[0081] The capsule may rotate about its longitudinal or central axis when air flows through the inhaler article. The capsule may be formed of an airtight material that may be pierced or punctured by a piercing element that may be separate or combined with the inhaler. The capsule may be formed of a metallic or polymeric material that serves to keep contaminates out of the capsule but may be pierced or punctured by a piercing element prior to consumption of the nicotine particles within the capsule. The capsule may be formed of a polymer material. The polymer material may be hydroxypropylmethylcellulose (HPMC). The capsule may be a size 1 to size 4 capsule, or a size 3 capsule.

[0082] The capsule may be nicotine-free. The capsule may comprise nicotine.

[0083] The capsule may contain nicotine particles comprising nicotine (also referred to as nicotine powder” or “nicotine particles”) and optionally particles comprising flavour (also referred to as “flavour particles). The capsule may contain a predetermined amount of nicotine particles and optional flavour particles. The capsule may contain enough nicotine particles to provide at least 2 inhalations or “puffs”, or at least about 5 inhalations or “puffs”, or at least about 10 inhalations or “puffs”. The capsule may contain enough nicotine particles to provide from about 5 to about 50 inhalations or “puffs”, or from about 10 to about 30 inhalations or “puffs”. Each inhalation or “puff” may deliver from about 0.1 mg to about 3 mg of nicotine particles to the lungs of the user or from about 0.2 mg to about 2 mg of nicotine particles to the lungs of the user or about 1 mg of nicotine particles to the lungs of the user.

[0084] The nicotine particles may have any useful concentration of nicotine based on the particular formulation employed. The nicotine particles may have at least about 1%wt nicotine up to about 30%wt nicotine, or from about 2%wt to about 25%wt nicotine, or from about 3%wt to about 20%wt nicotine, or from about 4%wt to about 15%wt nicotine, or from about 5%wt to about 13%wt nicotine. Preferably, about 50 to about 150 micrograms of nicotine may be delivered to the lungs of the user with each inhalation or “puff”. The capsule may hold or contain at least about 5 mg of nicotine particles or at least about 10 mg of nicotine particles. The capsule may hold or contain less than about 900 mg of nicotine particles, or less than about 300 mg of nicotine particles, or less than 150 mg of nicotine particles. The capsule may hold or contain from about 5 mg to about 300 mg of nicotine particles or from about 10 mg to about 200 mg of nicotine particles.

[0085] When flavour particles are blended or combined with the nicotine particles within the capsule, the flavour particles may be present in an amount that provides the desired flavour to each inhalation or “puff” delivered to the user.

[0086] The nicotine particles may have any useful size distribution for inhalation delivery preferentially into the lungs of a user. The capsule may include particles other than the nicotine particles. The nicotine particles and the other particles may form a powder system.

[0087] The capsule may hold or contain at least about 5 mg of a dry powder (also referred to as a powder system) or at least about 10 mg of a dry powder. The capsule may hold or contain less than about 900 mg of a dry powder, or less than about 300 mg of a dry powder, or less than about 150 mg of a dry powder. The capsule may hold or contain from about 5 mg to about 300 mg of a dry powder, or from about 10 mg to about 200 mg of a dry powder, or from about 25 mg to about 10 mg of a dry powder. The dry powder or powder system may have at least about 40%, or at least about 60%, or at least about 80%, by weight of the powder system comprised in nicotine particles having a particle size of about 5 micrometers or less, or in a range from about 1 micrometer to about 5 micrometers. The particles comprising nicotine may have a mass median aerodynamic diameter of about 5 micrometers or less, or in a range from about 0.5 micrometers to about 4 micrometers, or in a range from about 1 micrometer to about 3 micrometers or in a range from about 1.5 micrometers to about 2.5 micrometers. The mass median aerodynamic diameter is preferably measured with a cascade impactor. The particles comprising flavour may have a mass median aerodynamic diameter of about

[0088] 20 micrometers or greater, or about 50 micrometers or greater, or in a range from about 50 to about 200 micrometers, or from about 50 to about 150 micrometers. The mass median aerodynamic diameter is preferably measured with a cascade impactor.

[0089] The dry powder may have a mean diameter of about 60 micrometers or less, or in a range from about 1 micrometer to about 40 micrometers, or in a range from about 1.5 micrometers to about 25 micrometers. The mean diameter refers to the mean diameter per mass and is preferably measured by laser diffraction, laser diffusion or an electronic microscope.

[0090] Nicotine in the powder system or nicotine particles may be a pharmaceutically acceptable free-base nicotine, or nicotine salt or nicotine salt hydrate. Useful nicotine salts or nicotine salt hydrates include nicotine pyruvate, nicotine citrate, nicotine aspartate, nicotine lactate, nicotine bitartrate, nicotine salicylate, nicotine fumarate, nicotine mono-pyruvate, nicotine glutamate or nicotine hydrochloride, for example. The compound combining with nicotine to form the salt or salt hydrate may be chosen based on its expected pharmacological effect.

[0091] The nicotine particles preferably include an amino acid. Preferably the amino acid may be leucine such as L-leucine. Providing an amino acid such as L-leucine with the particles comprising nicotine, may reduce adhesion forces of the particles comprising nicotine and may reduce attraction between nicotine particles and thus reduce agglomeration of nicotine particles. Similarly, adhesion forces to particles comprising flavour may also be reduced thus agglomeration of nicotine particles with flavour particles is also reduced. The powder system described herein thus may be a free-flowing material and possess a stable relative particle size of each powder component even when the nicotine particles and the flavour particles are combined. Preferably, the nicotine may be a surface modified nicotine salt where the nicotine salt particle comprises a coated or composite particle. A preferred coating or composite material may be L-leucine. One particularly useful nicotine particle may be nicotine bitartrate with L-leucine.

[0092] The powder system may include a population of flavour particles. The flavour particles may have any useful size distribution for inhalation delivery selectively into the mouth or buccal cavity of a user.

[0093] The powder system may have at least about 40%, or at least about 60%, or at least about 80%, by weight of the population of flavour particles of the powder system comprised in particles having a particle size of about 20 micrometers or greater. The powder system may have at least about 40% or at least about 60%, or at least about 80%, by weight of the population of flavour particles of the powder system comprised in particles having a particle size of about 50 micrometers or greater. The powder system may have at least about 40% or at least about 60%, or at least about 80%, by weight of the population of flavour particles of the powder system comprised in particles having a particle size in a range from about 50 micrometer to about 150 micrometers.

[0094] The particles comprising flavour may include a compound to reduce adhesion forces or surface energy and resulting agglomeration. The flavour particle may be surface modified with an adhesion reducing compound to form a coated flavour particle. One preferred adhesion reducing compound may be magnesium stearate. Providing an adhesion reducing compound such as magnesium stearate with the flavour particle, especially coating the flavour particle, may reduce adhesion forces of the particles comprising flavour and may reduce attraction between flavour particles and thus reduce agglomeration of flavour particles. Thus, agglomeration of flavour particles with nicotine particles may also be reduced. The powder system described herein thus may possess a stable relative particle size of the particles comprising nicotine and the particles comprising flavour even when the nicotine particles and the flavour particles are combined. The powder system preferably may be free flowing.

[0095] Conventional formulations for dry powder inhalation contain carrier particles that serve to increase the fluidization of the active particles since the active particles may be too small to be influenced by simple airflow though the inhaler. The powder system may comprise carrier particles. These carrier particles may be a saccharide such as lactose or mannitol that may have a particle size greater than about 50 micrometers. The carrier particles may be utilized to improve dose uniformity by acting as a diluent or bulking agent in a formulation. The powder system utilized with the nicotine powder delivery system described herein may be carrier-free or substantially free of a saccharide such as lactose or mannitol. Being carrier- free or substantially free of a saccharide such as lactose or mannitol may allow the nicotine and to be inhaled and delivered to the user’s lungs at inhalation or airflow rates that are similar to typical smoking regime inhalation or airflow rates.

[0096] The nicotine particles and a flavour may be combined in a single capsule. As described above, the nicotine particles and a flavour may each have reduced adhesion forces that result in a stable particle formulation where the particle size of each component does not substantially change when combined. Alternatively, the powder system includes nicotine particles contained within a single capsule and the flavour particles contained within a second capsule.

[0097] The nicotine particles and flavour particles may be combined in any useful relative amount so that the flavour particles are detected by the user when consumed with the nicotine particles. Preferably the nicotine particles and flavour particles form at least about 90%wt or at least about 95%wt or at least about 99%wt or 10%wt of the total weight of the powder system. The inhaler and inhaler system may be less complex and have a simplified airflow path as compared to conventional dry powder inhalers. Advantageously, rotation of the capsule within the inhaler body aerosolizes the nicotine particles or powder system and may assist in maintaining a free-flowing powder. Thus, the inhaler article may not require the elevated inhalation rates typically utilized by conventional inhalers to deliver the nicotine particles described above deep into the lungs.

[0098] The inhaler article may use a flow rate of less than about 5 L / min or less than about 3 L / min or less than about 2 L / min or about 1.6 L / min. Preferably, the flow rate may be in a range from about 1 L / min to about 3 L / min or from about 1.5 L / min to about 2.5 L / min. Preferably, the inhalation rate or flow rate may be similar to that of Health Canada smoking regime, that is, about 1.6 L / min.

[0099] The inhaler system may be used by a user like smoking a conventional cigarette or vaping an electronic cigarette. Such smoking or vaping may be characterized by two steps: a first step during which a small volume containing the full amount of nicotine desired by the user is drawn into the mouth cavity, followed by a second step during which this small volume comprising the aerosol comprising the desired amount of nicotine is further diluted by fresh air and drawn deeper into the lungs. Both steps are controlled by the user. During the first inhalation step the user may determine the amount of nicotine to be inhaled. During the second step, the user may determine the volume for diluting the first volume to be drawn deeper into the lungs, maximizing the concentration of active agent delivered to the airway epithelial surface. This smoking mechanism is sometimes called “puff-inhale-exhale”.

[0100] The pharmaceutically active particles may have a mass median aerodynamic diameter of about 5 micrometers or less, or in a range from about 0.5 micrometers to about 4 micrometers, or in a range from about 1 micrometer to about 3 micrometers.

[0101] The capsule may further contain a second population of flavour particles having a mass median aerodynamic diameter of about 20 micrometers or greater, or about 50 micrometers or greater, or in a range from about 50 to about 200 micrometers, or from about 50 to about 150 micrometers.

[0102] The term “nicotine” refers to nicotine and nicotine derivatives such as free-base nicotine, nicotine salts and the like.

[0103] The term “flavourant” or “flavour” refers to organoleptic compounds, compositions, or materials that alter and are intended to alter the taste or aroma characteristics of nicotine during consumption or inhalation thereof.

[0104] The terms “upstream” and “downstream” refer to relative positions of elements of the holder, inhaler article and inhaler systems described in relation to the direction of inhalation air flow as it is drawn through the body of the holder, inhaler article and inhaler systems.

[0105] The terms “proximal” and “distal” are used to describe the relative positions of components, or portions of components, of the holder, inhaler article, or system. Holders or elements (such as the sleeve) forming the holder, according to the invention have a proximal end which, in use, receives an inhaler article and an opposing distal end which may be a closed end, or have an end closer to the proximal end of the holder. Inhaler articles, according to the invention have a proximal end. In use, the nicotine particles exit the proximal end of the inhaler article for delivery to a user. The inhaler article has a distal end opposing the proximal end. The proximal end of the inhaler article may also be referred to as the mouth end.

[0106] The holder for an inhaler article described herein may be combined with an inhaler article containing a capsule for activating the inhaler article by piercing the capsule, providing reliable activation of the capsule (by puncturing the capsule with the piercing element of the holder) within inhaler article, and releasing the particles contained inside the capsule and enabling the article to deliver the particles to a user. The holder is separate from the inhaler article, but the user may utilize both the inhaler article and the holder while consuming the particles released within the inhaler article. A plurality of these inhaler articles may be combined with a holder to form a system or kit. A single holder may be utilized on 10 or more, or 25 or more, or 50 or more, or 10 or more, inhaler articles to activate (puncture or pierce) a capsule contained within each inhaler article and provide reliable activation and optionally, a visual indication (marking), for each inhaler article of the activation of the inhaler article.

[0107] The holder for an inhaler article described herein may be combined with an inhaler article containing a capsule for activating the inhaler article by piercing the capsule, providing reliable activation of the capsule (by puncturing the capsule with the piercing element of the holder) within inhaler article, and releasing the particles contained inside the capsule and enabling the article to deliver the particles to a user. The holder is separate from the inhaler article, but the user may utilize both the inhaler article and the holder while consuming the particles released within the inhaler article. A plurality of these inhaler articles may be combined with a holder to form a system or kit. A single holder may be utilized on 10 or more, or 25 or more, or 50 or more, or 10 or more, inhaler articles to activate (puncture or pierce) a capsule contained within each inhaler article and provide reliable activation and optionally, a visual indication (marking), for each inhaler article of the activation of the inhaler article.

[0108] An inhaler system comprises an inhaler article and a holder for an inhaler article as described herein. The sleeve of the holder retains the inhaler article received in the sleeve cavity. A capsule may be disposed within the inhaler article body. An inhaler article may comprise a body extending along an inhaler longitudinal axis from a mouthpiece end to a distal end. A capsule cavity may be defined within the body bounded downstream by a filter element and bounded upstream by a tubular element defining a central passage. The central passage may form an air-inlet aperture extending from the distal end of the body towards the capsule cavity. A capsule may be disposed within the capsule cavity, wherein the central passage may have a smaller diameter then the capsule. Thus, the capsule may not pass through the central passage and is retained within the capsule cavity.

[0109] Below, there is provided a non-exhaustive list of non-limiting examples. Any one or more of the features of these examples may be combined with any one or more features of another example, embodiment, or aspect described herein.

[0110] Example 1: An inhaler article, comprising: a tubular body comprising an inner airflow channel extending between a mouth end of the tubular body and a distal end of the tubular body; a cavity for receiving an aerosol forming substrate, the cavity being arranged in the tubular body between the mouth end and the distal end; and a resealable retention element arranged at a position distal to the cavity, wherein the resealable retention element is configured to be switchable between an open position and a closed position, wherein, in the open position, the distal end of the tubular body is fluidly connected to the cavity, and wherein, in the closed position, the distal end of the tubular body is fluidly isolated from the cavity.

[0111] Example 2: The inhaler article according to Example 1 , wherein the resealable retention element is configured to switch between the open position and the closed position in dependence of the presence or absence of a pressure difference in the inner airflow channel generated between the mouth end and the distal end of the tubular body.

[0112] Example 3: The inhaler article according to Example 2, wherein the resealable retention element is configured to move towards the open position when a negative pressure is applied at the mouth end, and wherein the resealable retention element is configured to move back towards the closed position in absence of the negative pressure.

[0113] Example 4: The inhaler article according to any of the preceding Examples, wherein the resealable retention element comprises a flexible portion, the flexible portion being movable between a relaxed configuration when the resealable retention element is in the closed position and a tense configuration when the resealable retention element is in the open position.

[0114] Example 5: The inhaler article according to Example 4, wherein the resealable retention element is configured as a diskette, the diskette comprising one or more weakening lines to provide one or more flexible flaps, and wherein the flexible portion is provided by the one or more flexible flaps.

[0115] Example 6: The inhaler article according to Example 5, wherein the one or more weakening lines are perforation lines or cut lines.

[0116] Example 7: The inhaler article according to Example 5 or Example 6, wherein the diskette comprises two orthogonally arranged weakening lines to provide four equally sized flexible flaps.

[0117] Example 8: The inhaler article according to any of Example 1 to 3, wherein the resealable retention element comprises a one-way valve, optionally wherein the one-way valve comprises a valve flap being movable between the closed position and the open position.

[0118] Example 9: The inhaler article according to any of the preceding Examples, comprising a flanged front plug arranged at the distal end of the tubular body, wherein the distal end of the tubular body is at least partially closed by the flanged front plug. Example 10: The inhaler article according to Example 9, wherein the resealable retention element is affixed to the flanged front plug, preferably wherein the resealable retention element is affixed to an inside face of the flanged front plug.

[0119] Example 11 : The inhaler article according to Example 9, wherein the resealable retention element is affixed to an outside face of the flanged front plug.

[0120] Example 12: The inhaler article according to any of Examples 1 to 9, wherein the resealable retention element is affixed to the distal end of the tubular body by a connection wrapper.

[0121] Example 13: The inhaler article according to Example 12, wherein the connection wrapper is a paper overwrap.

[0122] Example 14: The inhaler article according to any of the preceding Examples, comprising a retention plug, wherein the retention plug is positioned between the cavity and the proximal end.

[0123] Example 15: The inhaler article according to Example 14, wherein the retention plug comprises bioplastic.

[0124] Example 16: The inhaler article according to any of the preceding Examples, wherein the resealable retention element comprises at least one of tobacco, cotton, paper, rayon, cork, latex, a starch-based plastic material, and silicone.

[0125] Example 17: The inhaler article according to any of the preceding Examples, wherein the tubular body comprises cardboard.

[0126] Example 18: The inhaler article according to any of the preceding Examples, wherein the cavity is a capsule cavity configured to receive a capsule comprising the aerosolforming substrate.

[0127] Example 19: The inhaler article according to Example 18, wherein the capsule is a pierceable capsule comprising pharmaceutically active particles in form of a dry powder, optionally wherein the pharmaceutically active particles comprise nicotine.

[0128] Example 20: The inhaler article according to any of the preceding Examples, wherein the resealable retention element is a sponge- or foam-like element as described herein.

[0129] Example 21 : The inhaler article according to any of Examples E1 to E19, wherein the resealable retention element is provided as a film as described herein.

[0130] Example 22: An inhaler system, comprising the inhaler article according to any of the preceding Examples and a holder, wherein the holder comprises a holder cavity configured to receive at least a distal portion of the inhaler article.

[0131] Example 23: The inhaler system according to Example 22, wherein the resealable retention element is configured to form an interference fit with a corresponding face of the holder. Example 24: The inhaler system according to Example 22 or 23, wherein the holder comprises a piercing means arranged for piercing into the cavity of the inhaler article when the inhaler article is being received in the holder cavity.

[0132] Features described in relation to one embodiment may equally be applied to other embodiments of the invention.

[0133] The invention will be further described, by way of example only, with reference to the accompanying drawings in which:

[0134] Fig. 1 shows an inhaler article;

[0135] Figs. 2a and 2b show a resealable retention element;

[0136] Fig. 3a shows a resealable retention element;

[0137] Figs. 3b and 3c show an inhaler article;

[0138] Fig. 4 shows an inhaler system;

[0139] Fig. 5 shows an inhaler article after use;

[0140] Figs. 6a and 6b show inhaler articles;

[0141] Fig. 7a shows resealable retention elements;

[0142] Fig. 7b shows a method for manufacturing a resealable retention element; and

[0143] Figs. 8a and 8b show inhaler articles.

[0144] Fig. 1 shows an inhaler article 10 in a cross-sectional view. The inhaler article 10 comprises a tubular body 12 comprising an inner airflow channel extending between a mouth end 14 of the tubular body 12 and a distal end comprising a flanged front plug 16 of the tubular body 12. The inhaler article 10 comprises a cavity 18 for receiving an aerosol forming substrate. The cavity 18 is arranged in the tubular body 12 between the mouth end 14 and the distal end comprising the flanged front plug 16. The inhaler article 10 comprises a retention plug 20. The retention plug 20 is positioned between the cavity 18 and the proximal end comprising the mouth end 14. The inhaler article 10 comprises an outer wrapper 38, for example a paper wrapper. The outer wrapper 38 may allow to provide user information printed thereon. The inhaler article 10 comprises a pierceable capsule 22 containing the aerosol-forming substrate. The capsule 22 may comprise the aerosol-forming substrate in form of a dry powder. The capsule 22 is positioned within the cavity 18, formed from the tubular body 12. The cavity 18 is a capsule cavity. The cavity 18 is at least partially sealed at both the distal and proximal ends by the retention plug 20 and the flanged front plug 16, respectively.

[0145] The inhaler article 10 further comprises a resealable retention element 24 positioned below the flanged front plug 16. The resealable retention element 24 is positioned in the cavity 18. The outside edge of resealable retention element 24 may be affixed to the inside face of the tubular body 12, for example via gluing. The resealable retention element 24 is configured to be switchable between an open position and a closed position. In the shown closed position, the distal end of the tubular body 12 is fluidly isolated from the cavity 18. The inhaler article 10 may thus reduce or avoid leakage of substances in the cavity 18 out of the distal end 16.

[0146] Figs. 2a and 2b show an embodiment of the resealable retention element 24 suitable for use in the inhaler article 10 of Fig. 1.

[0147] In Fig. 2a, a top view of the resealable retention element 24 in form of a diskette is shown. The diskette is shaped as a flat right circular cylinder. The diskette comprises weakening lines 26. The weakening lines 26 may be perforation lines or cut lines.

[0148] In Fig. 2b, a side view of the resealable retention element 24 in form of a diskette of Fig. 2a is shown. Suitable dimensions associated with the diskette-shaped resealable retention element 24 are shown. A diameter (A) of the diskette-shaped resealable retention element 24 may be between 5 millimeters and 13 millimeters, preferably between 6 millimeters and 11 millimeters, more preferably between 7 millimeters and 9 millimeters. A height (B) of the diskette-shaped resealable retention element 24 may be between 0.1 millimeter and 4 millimeters, preferably between 0.1 millimeter and 3 millimeters, more preferably between 0.1 millimeter and 2 millimeters. The lines of weakness 26 are configured to allow the diskette to open and thus to allow an airflow through the cavity 18 during use. For example, the lines of weakness 26 may be imparted onto the resealable retention element 24 with a laser perforation machine, perforation wheels or needle perforating equipment, as used in cigarette manufacturing to apply ventilation holes.

[0149] In the embodiment shown, the resealable retention element 24 of Fig. 2 comprises two orthogonally arranged weakening lines 26 to provide four equally sized flexible flaps. These flexible flaps collectively constitute the flexible portion of the resealable retention element 24. The incorporation of these flaps by the weakening lines, may endow the retention element with the necessary adaptability for its operational modes.

[0150] Fig. 3a shows again the resealable retention element 24 of Fig. 2a. Fig. 3b shows the resealable retention element 24 of Figs. 2a and 3a being installed in an inhaler article 10 and being in the open position, viewed along a cross-section (X) as indicated in Fig. 3a. In the open position shown in Fig. 3b, the four equally sized flexible flaps constituting the flexible portions of the resealable retention element 24 are bent open towards the proximal end of the inhaler article 10. This bending into the open position may be caused by a negative pressure applied at the mouth end of the article, for example by the drawing action of a user. When the user stops drawing, the flaps may bend back into the closed position, for example as shown in Fig. 1. This may offer the possibility to open and seal the flanged front plug 16. The resealable retention element 24 is thus configured to move towards the open position when a negative pressure is applied at the mouth end 14. The resealable retention element 24 is further configured to move back towards the closed position in absence of the negative pressure. This may prevent leakage.

[0151] Fig. 3c further illustrates the open state of the resealable retention element 24 within the inhaler article 10 of Fig. 1. As previously detailed, the inhaler article 10 features a tubular body 12 with an inner airflow channel that stretches between the mouth end 14 and the distal end holding a flanged front plug 16. Positioned within this tubular body 12, between the mouth end 14 and the distal end, is a cavity 18 configured to receive an aerosol-forming substrate. Additionally, the inhaler article 10 includes a retention plug 20, situated between the cavity 18 and the proximal end. The inhaler article 10 comprises a paper wrap 38. Inside the inhaler article 10, a pierceable capsule 22 containing the active substance is positioned within a capsule cavity 18, which is partially sealed by a retention plug 20 and a flanged front plug 16 at the proximal and distal ends, respectively.

[0152] Fig. 4 shows an embodiment of an inhaler system, comprising the inhaler article 10 of Fig. 1a and a holder 28. The holder 28 comprises a holder cavity configured to receive a distal portion of the inhaler article 10. The holder 28 comprises a piercing means (not shown) to pierce the capsule 22 at piercing point 30. In addition, the holder 28 opens the flanged front plug 16 by folding it inwardly. Further, the holder 28 opens the resealable retention element 24 by folding the four movable flaps inwardly. An interference fit is formed with a corresponding face of the holder 28. The inhaler article 10 is further held within the holder 28during use due to the interference fit. When the user inhales, an airflow 32 is created. The airflow 32 may act to rotate the capsule within the cavity 18 and against the retention plug 20. The rotational movement of the capsule may promote release of powder from the capsule through centrifugal force. This may create a powder flow 34. The powder flow 34 may then travel through retention plug 20, through mouth plug 14 to powder exit 36, where it may be inhaled by the user.

[0153] Fig. 5 shows the inhaler article 10 of Fig. 4 after removal from the holder 28. The resealable retention element 24 has returned to its original position preventing powder flow 34 forming powder leakage 36 outside of the inhaler article 10. In this way, powder leakage may be reduced or prevented. This may ensure higher safety and user convenience.

[0154] Fig. 6a shows an inhaler article 10. In difference to the inhaler article 10 of Fig. 1 , in the inhaler article 10 of Fig. 6a, the resealable retention element 24 is positioned outside of the capsule cavity 18 and affixed to the flanged front plug 16 of the tubular body 12.

[0155] Fig. 6b shows an inhaler article 10. In difference to the inhaler article 10 of Fig. 1 , in the inhaler article 10 of Fig. 6b, the resealable retention element 24 is positioned at the end of the open main tube 12, with no front flanging present. The resealable retention element 24 is formed as a diskette. The diskette is affixed into position via an additional connection wrapper 40. The wrapper may facilitate a secure and reliable connection between the element and the tubular body, ensuring the retention element's proper positioning and functionality.

[0156] The additional connection wrapper 40 may be a paper overwrap. The additional connection wrapper 40 may provide a practical and accessible means of securing the resealable retention element 24 to the distal end of the tubular body 12. The utilization of the additional connection wrapper 40 may ensure a functional and user-friendly connection while maintaining a cohesive aesthetic within the inhaler article's 10 design.

[0157] Fig. 7a shows three different resealable retention elements 24 for use in an inhaler article 10 as described herein in top views. The resealable retention elements 24 of Fig. 7a are sponge- or foam-like elements 24. The sponge- or foam-like element 24 comprises a sponge- or foam-like material. The sponge- or foam-like material may be any type of sponge known to the skilled person. For example, a polymeric sponge, a cellulose-based sponge, a synthetic sponge, or any combination thereof. A cellulose-based sponge may advantageously be fully sustainable.

[0158] The density of the sponge- or foam-like element 24 together with the elasticity of the constituting material may define the efficacy of the element in opening and closing following insertion into and removal from the holder 28. The thickness of the sponge- or foam-like element 24 may also be varied for optimizing the sealing efficiency and efficacity in dependence of a specific embodiment. For example, a force needed for insertion may be reduced when reducing the thickness and vice versa.

[0159] The sponge- or foam-like element 24 may comprise one or more weakening lines 26.

[0160] The weakening lines 26 may be provided as cutting lines 26. Various cutting shapes are possible. By varying the cutting shapes, the behavior of the element in opening and closing following insertion into and removal from the holder 28 may be varied. For example, a force needed for insertion may be reduced when increasing the number of cutting lines 26.

[0161] By varying the cutting shapes, the sponge- or foam-like element 24 may thus be optimized in dependance of the requirements of a specific embodiment.

[0162] Fig. 7a shows an embodiment of the sponge- or foam-like element 24 comprising one cutting line 26 on the left-hand side, an embodiment of the sponge- or foam-like element 24 comprising two cutting lines 26 in the middle, and an an embodiment of the sponge- or foamlike element 24 comprising three cutting lines 26 on the right-hand side.

[0163] The cutting lines 26 may be provided in any desired shape. For example, a crossshape having two perpendicular, or not fully perpendicular, straight cutting lines 26 as exemplarily shown in the middle of Fig. 7a. For example, a simple linear cutting line 26 as exemplarily shown on the left-hand side of Fig. 7a. For example, asterisk-like shapes comprising multiple straight lines 26 crossing each other at same or different angles as exemplarily shown on the right-hand side of Fig. 7a.

[0164] The cutting lines 26 may be provided so as to not completely protrude through the sponge- or foam-like element 24 along a direction parallel to the longitudinal axis of the inhaler article 10 when the resealable retention element 24 is installed in the inhaler article 10.

[0165] The cutting lines 26 may be provided by pre-cutting into a section of a sheet-like precursor of the sponge- or foam-like element 24, before bringing the precursor of the sponge- or foam-like element 24 into its final shape to obtain the final sponge- or foam-like element 24.

[0166] For example, the sponge- or foam-like element 24 may have a cylindrical shape. The cylindrical shape may be configured to closely fit into or onto the tubular body 12. The cylindrical shape may be configured to have a larger diameter than the inner diameter of the tubular body 12. Thereby, the sponge- or foam-like element 24 may be compressed when being inserted into the tubular body 12. This may, for example, improve adherence of the sponge- or foam-like element 24 in the tubular body 12.

[0167] The sponge- or foam-like element 24 may be provided as a sheet or stripe of material which is rolled inside the cylindrical wall inside the tubular body 12. The sheet or stripe of material may comprise one or more pre-cuts all along the stripe or sheet. For example, the sheet or stripe of material may comprise plural pre-cuts all along the stripe or sheet so that once rolled and inserted into the tubular body 12, a shape of the cutting lines 26, such as an above-described asterisk-like shape, will form. A suitable method is exemplary described below in conjunction with Fig. 7b.

[0168] Fig. 7b shows a method for manufacturing a resealable retention element 24. The left-hand side of Fig. 7b shows the result of a first step of providing a precursor of the resealable retention element 24 in form of a sheet 23 of a sponge- or foam-like material. The middle of Fig. 7b shows the result of an optional subsequent step of providing one or more pre-cuts into the sheet 23. The optional pre-cuts do not extent fully through the sheet 23 such that the sheet 23 remains intact. The right-hand side of Fig. 7b shows the result of a final step of rolling the sheet 23 into a cylindrical form to obtain the final resealable retention element 24 in form of a cylindrical sponge- or foam-like element 24, optionally comprising a plurality of cutting lines 26 in an asterisk-like shape. A line 25, where the opposing ends of the rolled sheet 23 meet, is indicated for illustrative purposes. The line 25 may be invisible, or nearly invisible, for a user’s eyes. The opposing ends may contact each other to provide a tight seal at the line 25. The opposing ends may be elastic and may press onto each other to provide a tight seal at the line 25. The opposing ends may be affixed to one another, for example by the application of glue.

[0169] The sponge- or foam-like element 24 may be provided with one or more cutting lines 26, or without any cutting lines 26. When no cutting lines 26 are present, the elasticity of the material alone may allow for an easy and convenient insertion of the inhaler article 10 into the holder 28, and a subsequent return to the original shape on removal of the article 10 from the holder 28. The sponge- or foam-like element 24 may be of any color.

[0170] The sponge- or foam-like element 24 may be provided as a single-piece element. The sponge- or foam-like element 24 may be provided as a monolithic piece. The sponge- or foam-like element 24 may be provided as multiple layers of thin sponges or foams.

[0171] For example, the sponge- or foam-like element 24 may be attached to the inhaler stick 10 by gluing, by a double-side adhesive, or by sewing. The sponge- or foam-like element 24 may be attached to the inhaler stick 10 by any a mechanical or chemical means known to the skilled person as being suitable to keep the element in the desired position.

[0172] The sponge- or foam-like element 24 may be provided in dry form. The sponge- or foam-like element 24 may be provided in humid form, for example having a water content of at least 1 percent by weight, optionally at least two percent by weight, optionally at least 5 percent by weight, optionally at least 10 percent by weight. Providing a humid sponge- or foam-like element 24 may improve retaining powder released from a capsule 22 after use, in particular dry powder.

[0173] Figs. 8a and 8b show distal portions of inhaler articles 10 in perspective views. The resealable retention element 24 may be provided as a film. The film is formed from a filmforming material. The film-forming material may be a water-based binder. The water-based binder may comprise an acrylic copolymer. The water-based binder may be cross-linkable by UV (ultraviolet) light. The water-based binder may be a water-based binder from the group available from Swiss company “Archroma Management GmbH” under the tradename “Appretan®”.

[0174] The resealable retention element 24 comprising a film-forming material may be used in an inhaler article 10 comprising a flanged front plug 16 of the tubular body 12 as shown in Fig. 8a. The resealable retention element 24 comprising a film-forming material may be used in an inhaler article 10 comprising a curled distal end (not shown). The resealable retention element 24 comprising a film-forming material may be used in an inhaler article 10 comprising an open tubular body 12 as shown in Fig. 8b.

[0175] The resealable retention element 24 comprising a film-forming material may be substantially transparent.

[0176] The resealable retention element 24 comprising a film-forming material may have a thickness in a range from 1 micrometer to 5000 micrometers, preferably 10 micrometers to 2000 micrometers. The thickness may be measured in a direction parallel to the longitudinal axis of the inhaler article 10 when the resealable retention element 24 is installed in the inhaler article 10.

[0177] The film-forming material may be provided as a liquid solution. The liquid solution may be applied on flanged or curled tubes or on an open tubular body 12. For example, the liquid solution may be applied manually by using a paint-brush or tip-dipping the stick into the solution. For example, the liquid solution may be applied by spray application.

[0178] Once applied, the liquid solution typically needs from 5 minutes to 30 minutes to dry and settle, depending on the specific solution and on environmental conditions. The drying step may be accelerated. For example, the drying time may be shortened by employing a drying step. The drying step may comprise guiding the inhaler articles into a drying chamber. For example, a water-based binder which is cross-linkable by UV light may be used, and the drying step may be accelerated by using an UV lamp to accelerate settling and drying. This may allow to reduce the time of settling to few seconds. By reducing the drying time, manufacturing speed may be enhanced. Manufacturing costs may thereby be reduced.

[0179] After drying, the resealable retention element 24 comprising the film-forming material may be substantially transparent. After drying, the thickness of the resealable retention element 24 comprising the film-forming material may be in a range from 1 micrometer to 5000 micrometers, preferably 10 micrometers to 2000 micrometers.

[0180] The dried layer may be maintained as a closed layer in the final inhaler article 10. The closed layer may be perforated only during insertion of the inhaler article 10 into the holder 28. The dried layer may be cut or perforated in the final inhaler article before use, for example cut in the middle. This may facilitate insertion of the inhaler article 10 into the holder 28.

Claims

CLAIMS1. An inhaler article, comprising: a tubular body comprising an inner airflow channel extending between a mouth end of the tubular body and a distal end of the tubular body; a cavity for receiving an aerosol forming substrate, the cavity being arranged in the tubular body between the mouth end and the distal end; and a resealable retention element arranged at a position distal to the cavity, wherein the resealable retention element is configured to be switchable between an open position and a closed position, wherein, in the open position, the distal end of the tubular body is fluidly connected to the cavity, wherein, in the closed position, the distal end of the tubular body is fluidly isolated from the cavity, wherein the resealable retention element comprises a flexible portion, the flexible portion being movable between a relaxed configuration when the resealable retention element is in the closed position and a tense configuration when the resealable retention element is in the open position, wherein the resealable retention element is configured as a diskette, the diskette comprising one or more weakening lines to provide one or more flexible flaps, and wherein the flexible portion is provided by the one or more flexible flaps.

2. The inhaler article according to claim 1 , wherein the resealable retention element is configured to switch between the open position and the closed position in dependence of the presence or absence of a pressure difference in the inner airflow channel generated between the mouth end and the distal end of the tubular body.

3. The inhaler article according to claim 2, wherein the resealable retention element is configured to move towards the open position when a negative pressure is applied at the mouth end, and wherein the resealable retention element is configured to move back towards the closed position in absence of the negative pressure.

4. The inhaler article according to any of the preceding claims, wherein the one or more weakening lines are perforation lines or cut lines.

5. The inhaler article according to any of the preceding claims, wherein the diskette comprises two orthogonally arranged weakening lines to provide four equally sized flexible flaps.

6. The inhaler article according to any of the preceding claims, comprising a flanged front plug arranged at the distal end of the tubular body, wherein the distal end of the tubular body is at least partially closed by the flanged front plug.

7. The inhaler article according to claim 6, wherein the resealable retention element is affixed to an inside face of the flanged front plug, or wherein the resealable retention element is affixed to an outside face of the flanged front plug.

8. The inhaler article according to any of claims 1 to 6, wherein the resealable retention element is affixed to the distal end of the tubular body by a connection wrapper.

9. The inhaler article according to any of the preceding claims, comprising a retention plug, wherein the retention plug is positioned between the cavity and the mouth end.

10. The inhaler article according to any of the preceding claims, wherein the resealable retention element comprises at least one of tobacco, cotton, paper, rayon, cork, latex, a starch-based plastic material, and silicone.

11. The inhaler article according to any of the preceding claims, wherein the cavity comprises a capsule, the capsule comprising the aerosol-forming substrate.

12. The inhaler article according to claim 11, wherein the aerosol-forming substrate is provided as pharmaceutically active particles in form of a dry powder, optionally wherein the pharmaceutically active particles comprise nicotine.

13. An inhaler system, comprising the inhaler article according to any of the preceding claims and a holder, wherein the holder comprises a holder cavity configured to receive at least a distal portion of the inhaler article.

Images